The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We excluded acute coronary syndromes and left coronary trunk injury. The primary endpoint was death, myocardial infarction or stroke and the secondary main was the sum of…
TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.
TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel versus aspirin + prasugrel in patients admitted with acute coronary syndromes without ST-segment elevation and initially treated with a conservative strategy. The study concluded that the administration of prasugrel did not…
TACT trial: Chelation Therapy for the Treatment of Coronary Disease.
In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative stress of plates. The placebo-controlled double blind design study included 1708, randomized to EDTA + vitamins, EDTA + placebo, placebo + vitamins o placebo + placebo. Primary end…
CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.
A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were evaluated. Mortality and the occurrence of events were not different between the two groups. The cost of treatment was lower in the central vascular surgery centers (23,961 USD versus 25,540 USD,…
Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .
Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of bedside platelet function monitoring with drug adjustment vs. the conventional post DES therapy without monitoring and drug adjustment. It included 2466 patients with stable coronary disease or Non-ST Elevation…